Significant Ownership of BAKER BROS. ADVISORS LP

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for BAKER BROS. ADVISORS LP focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Scott L. Lessing - Scott L. Lessing/ President By: Baker Bros. Advisors (GP) LLC, its general partner
Manager location
New York, NY

Follow Filing Activity

Follow BAKER BROS. ADVISORS LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of BAKER BROS. ADVISORS LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
KOD Kodiak Sciences Inc. Common Stock, $0.0001 par value per share 33% $416,802,847 20,067,542 Baker Bros. Advisors LP 18 Dec 2025
ACAD ACADIA Pharmaceuticals Inc. Common Stock, $0.0001 par value per share 25% $1,162,886,859 43,294,373 Julian C. Baker 24 Feb 2026
SERA Sera Prognostics, Inc. Class A Common Stock, $0.0001 par value per share 16% $18,418,870 5,498,170 Baker Bros. Advisors LP 12 Feb 2025
INCY Incyte Corp Common Stock, $0.001 par value per share 16% $3,027,631,461 +$1,178,549 31,225,572 +0.04% Felix J. Baker 07 May 2026
PRLD Prelude Therapeutics Inc Common Stock, $0.0001 par value per share 16% $35,227,431 +$86,682 10,295,301 +0.25% Baker Bros. Advisors LP 20 Apr 2026
REPL Replimune Group, Inc. Common Stock, $0.001 par value per share 14% $99,960,291 11,045,336 Baker Bros. Advisors LP 07 Mar 2025
KYMR Kymera Therapeutics, Inc. Common Stock, $0.0001 par value per share 11% $551,236,913 +$127,711,627 8,676,797 +30% Baker Bros. Advisors LP 09 Dec 2025
ABCL AbCellera Biologics Inc. Common Shares, no par value per share 11% $120,824,425 33,012,138 Baker Bros. Advisors LP 30 Apr 2026
CELC Celcuity Inc. Common Stock, par value $0.001 per share 10% $510,332,489 -$492,227,789 4,877,963 -49% Baker Bros. Advisors LP 14 Jul 2026
DBVT DBV Technologies S.A. Ordinary shares, nominal value 0.10 euro per share 10% $490,489,821 +$40,190,632 25,586,190 +8.9% Baker Bros. Advisors LP 12 Jan 2026
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 10% $155,158,528 +$79,195,063 8,876,346 +104% Baker Bros. Advisors LP 31 Mar 2026
IMTX Immatics N.V. Ordinary Shares, nominal value EUR 0.01 per share 10% $103,041,681 +$16,402,644 12,094,094 +19% Baker Bros. Advisors LP 30 Sep 2025
GRAL GRAIL, Inc. Common Stock, par value $0.001 per share 9.8% $183,825,657 +$88,671,912 4,028,614 +93% Baker Bros. Advisors LP 31 Mar 2026
RYTM Rhythm Pharmaceuticals, Inc. Common Stock, par value $0.001 per share 8.9% $360,984,750 5,604,483 Baker Bros. Advisors LP 31 Mar 2025
ONC BeOne Medicines Ltd. Ordinary Shares, par value $0.0001 per share 8% $36,692,201,272 -$1,740,708 115,912,814 -0% Julian C. Baker 11 Jun 2026
NRIX Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share 7.2% $138,364,566 7,527,996 Baker Bros. Advisors LP 31 Dec 2025
KNSA Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares, nominal value $0.000273235 per share 7% $140,056,330 3,253,341 Julian C. Baker 21 May 2026
NGNE Neurogene Inc. Common Stock, par value $0.000001 per share 7% $21,254,360 -$10,597,328 991,804 -33% Julian C. Baker 30 Jun 2025
EWTX Edgewise Therapeutics, Inc. Common Stock, par value $0.0001 per share 6.9% $95,196,398 7,305,940 Baker Bros. Advisors LP 30 Jun 2025
PRAX Praxis Precision Medicines, Inc. Common Stock, par value $0.0001 per share 6.3% $564,862,864 1,753,198 Baker Bros. Advisors LP 31 Mar 2026
ALKS Alkermes plc. Ordinary Shares, $0.01 per share 6.1% $280,143,231 10,012,267 Baker Bros. Advisors LP 31 Dec 2025
STOK Stoke Therapeutics, Inc. Common Stock, par value $0.0001 per share 5.8% $105,906,763 3,336,697 Baker Bros. Advisors LP 31 Dec 2025
CERS Cerus Corporation Common Stock, par value $0.001 per share 5.2% $15,944,852 -$4,572,043 10,028,209 -22% Julian C. Baker 30 Sep 2025
CADL Candel Therapeutics, Inc. Common Stock, par value $0.01 per share 5% $11,882,723 -$2,550,075 2,455,108 -18% Baker Bros. Advisors LP 31 Mar 2025
RVMD Revolution Medicines, Inc. Common Stock, par value $0.0001 per share 4.9% $971,159,717 +$9,283,443 9,455,357 +0.97% Baker Bros. Advisors LP 31 Dec 2025
BMEA Biomea Fusion, Inc. Common Stock, par value $0.0001 per share 4% $3,194,378 1,451,990 Baker Bros. Advisors LP 31 Dec 2024
KALA KALA BIO, Inc. Common Stock, $0.001 par value per share 0.01% $509 -$635,303 2,312 -100% Baker Bros. Advisors LP 31 Mar 2026
IGMS IGM Biosciences, Inc. Common Stock, $0.01 par value per share 0% $0 0 Baker Bros. Advisors LP 14 Aug 2025

Schedules 13D/G Reported by BAKER BROS. ADVISORS LP:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .